Aligos Therapeutics Inc (ALGS) Stock Price, Quote & News

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 466 6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States

Orlandotrader Nov. 14 at 3:52 PM

$ALGS Back in.

0 · Reply

10PieceTeriyaki Nov. 14 at 12:43 PM

$ALGS boilinger support was always 6$ been waiting alrhough i think well see a new low some news would be goof too

0 · Reply

Bwnuts Nov. 13 at 9:09 PM

$ALGS it’s times like these where the board should be looking at leadership changes. This thing needs a major change in momentum quickly or it’s bedtime for Bonzo. Even retail shorts are looking at this seeing an opportunity to take it to 3.76. That’s where it’s heading. If there’s no fight there, it’s going one and below and the cycle starts over.

0 · Reply

HedgeUrHedge Nov. 13 at 6:39 PM

$ALGS Hope institutions realize were not selling any shares…quite the opposite. book value is $16 which means its trading almost 3 times below book value, they are not fooling anyone into selling.

1 · Reply

HedgeUrHedge Nov. 13 at 3:30 PM

$ALGS simple question…what justifies a 40M market cap with 2 phase 2 trials on going? :)

2 · Reply

HedgeUrHedge Nov. 13 at 3:25 PM

$ALGS Aligos is down over 98% so what exactly has brought it down FACTUAL- previous HBV drug failed, cash burn, J&J suing Aligos. Only overhang is cash burn, they now have a new hbv drug best and most likely first in class, they now have MASH drug with similar if not better than Madrigals drug results depending on phase 2 and 3 results…so why is it down this much. simple…wall street is betting on this to fail with running out of cash. everything else is just noise but if this has good phase 2 then back to 300/share. they have no reason to short otherwise. these are FACTS

0 · Reply

Bwnuts Nov. 13 at 5:58 AM

$ALGS @aletz

2 · Reply

Bwnuts Nov. 12 at 5:17 AM

$ALGS if you’re thinking “ it’s got to get better all the way down here. This is a great buying opportunity,” it gets worse every time without fail. I think this has performed so badly year after year that the only play is short. Shorts take a breather for 3 months, let retail think it reversed then slam it back down. The cycle repeats over and over again. Reverse split, pump, dilute short and repeat. Reverse split is next in the cycle.

1 · Reply

Bwnuts Nov. 11 at 5:29 PM

$ALGS cnbc talking about a biotech breakout over at $XBI looks like a biotech breakdown over here.

0 · Reply

Bwnuts Nov. 11 at 4:46 PM

$ALGS having fun yet with this very promising company down almost 50% in 4 months in a crazy strong bull market with $XBI up 30% in the same period?

0 · Reply

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 8:00 AM EST - 4 days ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Nov 6, 2025, 8:30 AM EST - 8 days ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 10 days ago

Aligos Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:30 AM EDT - 15 days ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

Oct 16, 2025, 8:30 AM EDT - 4 weeks ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Oct 14, 2025, 8:30 AM EDT - 4 weeks ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

Oct 7, 2025, 8:30 AM EDT - 5 weeks ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Sep 3, 2025, 4:05 PM EDT - 2 months ago

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 3 months ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Aug 13, 2025, 8:30 AM EDT - 3 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

Jun 18, 2025, 8:00 AM EDT - 5 months ago

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

May 29, 2025, 8:00 AM EDT - 6 months ago

Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:00 AM EDT - 6 months ago

Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal

May 8, 2025, 8:00 AM EDT - 6 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

May 6, 2025, 8:00 AM EDT - 6 months ago

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Apr 29, 2025, 8:30 AM EDT - 7 months ago

Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025

Apr 23, 2025, 4:05 PM EDT - 7 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

Mar 26, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025

Mar 10, 2025, 8:00 AM EDT - 8 months ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 9 months ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

Feb 12, 2025, 7:00 AM EST - 9 months ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Nov 19, 2024, 1:30 PM EST - 1 year ago

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Present at Investor Conferences in October

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Sep 18, 2024, 5:00 PM EDT - 1 year ago

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Reverse Stock Split

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Jul 22, 2024, 9:00 AM EDT - 1 year ago

Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

May 22, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

May 21, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

Mar 12, 2024, 4:05 PM EDT - 1 year ago

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 4:05 PM EST - 1 year ago

Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024

Feb 26, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 8:00 AM EST - 1 year ago

Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024

Dec 7, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Nov 20, 2023, 4:05 PM EST - 2 years ago

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Nov 10, 2023, 8:05 AM EST - 2 years ago

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Nov 3, 2023, 4:30 PM EDT - 2 years ago

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Orlandotrader Nov. 14 at 3:52 PM

$ALGS Back in.

0 · Reply

10PieceTeriyaki Nov. 14 at 12:43 PM

$ALGS boilinger support was always 6$ been waiting alrhough i think well see a new low some news would be goof too

0 · Reply

Bwnuts Nov. 13 at 9:09 PM

0 · Reply

HedgeUrHedge Nov. 13 at 6:39 PM

$ALGS Hope institutions realize were not selling any shares…quite the opposite. book value is $16 which means its trading almost 3 times below book value, they are not fooling anyone into selling.

1 · Reply

HedgeUrHedge Nov. 13 at 3:30 PM

$ALGS simple question…what justifies a 40M market cap with 2 phase 2 trials on going? :)

2 · Reply

HedgeUrHedge Nov. 13 at 3:25 PM

0 · Reply

Bwnuts Nov. 13 at 5:58 AM

$ALGS @aletz

2 · Reply

Bwnuts Nov. 12 at 5:17 AM

1 · Reply

Bwnuts Nov. 11 at 5:29 PM

$ALGS cnbc talking about a biotech breakout over at $XBI looks like a biotech breakdown over here.

0 · Reply

Bwnuts Nov. 11 at 4:46 PM

$ALGS having fun yet with this very promising company down almost 50% in 4 months in a crazy strong bull market with $XBI up 30% in the same period?

0 · Reply

Teeemo16 Nov. 9 at 8:11 PM

$ALGS BOOM “HBV antigen and HBV RNA reduction was maintained during NA only 8-week follow-up”

0 · Reply

HedgeUrHedge Nov. 8 at 7:11 PM

$ALGS funny how all these MASH companies have multi-billion dollar market caps, yet Aligos has a less than 100 million dollar market cap with 2 phase 2 drugs in different spaces. Heavy manipulation has consequences. hope they enjoy jail time bc there are receipts on the backend we have to trace it lol. Good Luck :)

1 · Reply

HedgeUrHedge Nov. 7 at 7:38 PM

$ALGS 4% of the float is shorted? Not sure if that is accurate so someone has some explaining to do.....hmmmm

1 · Reply

HedgeUrHedge Nov. 7 at 7:31 PM

$ALGS im back....and suggest you keep shorting it please :)

1 · Reply

Buyhighsellatlow Nov. 7 at 1:58 AM

$ALGS I hate to say it but I think this one is going to the $3’s or even the $2’s. Promising technology but management is dreadful at…managing. Expensive mistake this one was…at least I’ll get to write off a portion.

1 · Reply

aletz Nov. 6 at 9:15 PM

$ALGS New preclinical and clinical findings reported by other companies have suggested that THR-β agonists can significantly enhance weight loss when administered in combination with incretin receptor agonists (RAs) for the treatment of obesity. We recently generated preclinical data combining our proprietary THR-β agonist, ALG-055009, with incretin RAs in a diet-induced obese (DIO) mouse model. ALG-055009 exhibited profound synergistic effects when used in combination with semaglutide or tirzepatide. The combination therapy also demonstrated enhanced antihyperlipidemic effects as compared to monotherapy. We plan to present these data at a future scientific conference.

2 · Reply

Bwnuts Nov. 6 at 5:20 PM

$ALGS Bear Case-so now you get a drug approved and the government caps your price. Bull Case- GLP1 become more accessible increasing TAM for ALGS. NET NET….$ALGS is still structurally broken because of bad management and terrible financings. Another crappy financing is right around the corner.

0 · Reply

d_risk Nov. 6 at 4:47 PM

$ALGS - Aligos Therapeutics, Inc. - 10Q - Updated Risk Factors ALGS flags heightened going concern risk amid ongoing losses and cash burn, expanded detail on unpredictable results, regulatory and clinical trial hurdles, global and pandemic disruptions, IP and commercialization threats, new risks from market volatility, insurance, and public company compliance, plus extensive new disclosures on patent, personnel, and operational vulnerabilities. #Biotechnology #MarketVolatility #FinancialRisk #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/ALGS/10-Q/2025-11-06

0 · Reply

Zezed1 Nov. 4 at 2:42 PM

$ALGS well I was wrong about this one

1 · Reply

aletz Nov. 4 at 2:03 PM

$ALGS MASH asset still promising

0 · Reply

aletz Nov. 4 at 2:02 PM

$ALGS If you watch the latest presentation by CEO during Liver Disease Conference held last month, at around 31:30, he talks about a study waiting for an acceptance, and gives slight hint that it's about ALGS's MASH drug improving weight loss, reducing plateau effect when combined with Incretic Receptor Agonist (GLP-1 weight loss drugs). It seems that this abstract has been submitted for late-breaking abstract for the upcoming Liver Meeting at AASLD, and it would be a nice catalyst to have if accepted. https://journey.ct.events/view/7252d41f-6d94-4f3d-8f85-d75fc1fe6cc7

0 · Reply

Bwnuts Nov. 4 at 2:55 AM

$ALGS 7, 5 or 3.50. History says silence for a long time and it goes to 3.50. Has anyone heard from the company? They see the chart just like everyone else, they’re just not interested in it or they don’t have a plan. Pick your poison. Any capable CEO would see this chart and think….we’re really undervalued, the market doesn’t quite see/understand what we’re doing. I should work on that.

1 · Reply

Market Cap	37.34M
Revenue (ttm)	3.95M
Net Income (ttm)	-131.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,321.77%
Debt to Equity Ratio	0.00

Volume	72,000
Avg Vol	84,674
Day's Range	N/A - N/A
Shares Out	6.15M
Stochastic %K	45%
Beta	2.76
Analysts	Strong Sell
Price Target	$95.00